A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis.

Trial Profile

A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Tapentadol (Primary) ; Oxycodone
  • Indications Osteoporotic pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2010 Actual number of patients (108) added as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top